The estimated Net Worth of John J. Kirby is at least $643 Thousand dollars as of 17 December 2021. Mr. Kirby owns over 10,000 units of Idera Pharmaceuticals stock worth over $16,182 and over the last 6 years he sold IDRA stock worth over $21,003. In addition, he makes $605,649 as Chief Financial Officer and Senior Vice President at Idera Pharmaceuticals.
John has made over 5 trades of the Idera Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of IDRA stock worth $6,200 on 17 December 2021.
The largest trade he's ever made was buying 10,000 units of Idera Pharmaceuticals stock on 17 December 2021 worth over $6,200. On average, John trades about 1,408 units every 51 days since 2019. As of 17 December 2021 he still owns at least 37,632 units of Idera Pharmaceuticals stock.
You can see the complete history of Mr. Kirby stock trades at the bottom of the page.
John J. Kirby CPA serves as Chief Financial Officer, Senior Vice President of the Company. He joined the Company in 2015 as the Company’s Vice President of Accounting and has served as Vice President of Finance since July 2018. Prior to joining the Company, Mr. Kirby served as Assistant Controller at Endo Pharmaceuticals, Inc. from November 2014 to October 2015. From August 2012 to July 2014, Mr. Kirby served as Vice President, Chief Accounting Officer and Corporate Controller at ViroPharma Incorporated. Mr. Kirby began his career at KPMG, LLP and served as a Regional Audit Director at AstraZeneca Pharmaceuticals prior to joining ViroPharma Incorporated. Mr. Kirby received his Bachelor of Science in Accountancy from Villanova University and is a licensed certified public accountant in the Commonwealth of Pennsylvania.
As the Chief Financial Officer and Senior Vice President of Idera Pharmaceuticals, the total compensation of John Kirby at Idera Pharmaceuticals is $605,649. There are 3 executives at Idera Pharmaceuticals getting paid more, with Vincent Milano having the highest compensation of $1,337,220.
John Kirby is 47, he's been the Chief Financial Officer and Senior Vice President of Idera Pharmaceuticals since 2019. There are 17 older and no younger executives at Idera Pharmaceuticals. The oldest executive at Idera Pharmaceuticals, Inc. is Dr. Sudhir Agrawal D.Phil., DPHIL, F.R.S.C., 67, who is the Scientific Advisor.
John's mailing address filed with the SEC is 505 Eagleview Blvd, Exton, PA 19341, USA.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro..., and Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: